The rest of us have already delved into the Several annual link to Alfred Research hospital in AU and are quite satisfied that the will continue to support the additional test as announced the other day. As to what Anavex actually spent for the previous tests done in AU land.
There has never been one iota of evidence presented that the AU govt. provided any directed monetary assistance to AVXL other than their tax credit (incentive probably a better word as per Investor2014's post) program.
There has never been one iota of evidence presented that the Alfred Research Hospital or their staff provided any assistance to AVXL that AVXL didn't pay for.
I second the call for you to provide any such evidence. Furthermore if, as you say, "kept track of Anavex's quarterly books and estimate the monies they spent and where they were spent you might understand" that they specifically pointed to the Phase 2a trial as a reason their R&D costs jumped. They spent $2.24M in 2014, $4.84M in 2015, and $7.3M in 2016. The Phase 2a started in 12/14 so even if you ignore start up costs from 2014 and only attribute 50% of 2015 and 2016 R&D spending to their primary research endeavor of the time (a gross underestimate) then they spent over $6M on the Phase 2a....that's $190K per subject. That is NOT cheap...and, while underestimating costs in 2015 and 2016 ignores costs from earlier and ignores continuing costs to this day.
Market Data 
Markets 
AI
